Population Pharmacokinetics (PopPK)
From PubPK
Population pharmacokinetics is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses of a drug of interest . Certain patient demographic, pathophysiological, and therapeutical features, such as body weight, excretory and metabolic functions, and the presence of other therapies, can regularly alter dose-concentration relationships. For example, steady-state concentrations of drugs eliminated mostly by the kidney are usually greater in patients suffering from renal failure than they are in patients with normal renal function receiving the same drug dosage. Population pharmacokinetics seeks to identify the measurable pathophysiologic factors that cause changes in the dose-concentration relationship and the extent of these changes so that, if such changes are associated with clinically significant shifts in the therapeutic index, dosage can be appropriately modified (FDA 1999).
See Also
External links
- Guidance for Industry: Population Pharmacokinetics Guidance by FDA
- NONMEM
- MONOLIX
- BUGS (Bayesian inference Using Gibbs Sampling)
- Population Approach Group in Europe (PAGE)
- A web-based learning resource for pharmacometrics
References
- Aarons L (1991) Population Pharmacokinetics: Theory and Practice Br J Clin Pharmacol' 32:669-670.
- FDA (1999) Guidance for Industry: Population Pharmacokinetics
- Sheiner LB, Rosenberg B, Marathe VV (1977) Estimation of Population Characteristics of Pharmacokinetic Parameters from Routine Clinical Data J Pharmacokin Biopharm 5:445–79
